SubsidieMeestersautomated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Projectdetails
Introduction
The NEXUS project will develop an easily customizable integrated platform to enable Extracellular Vesicles (EVs) separation, purification, and multivariate characterization from complex biofluids. EVs enclose a heterogeneous group of cell-released membranous vesicles, abundantly present in body fluids from which they can be extracted in a non-invasive manner.
Importance of EVs
Their surface markers and cargo (proteins, nucleic acids, glycans, lipids) represent an ideal source of diagnostic, prognostic, and efficacy biomarkers, providing real-time information on tissue homeostasis alterations. However, their detection and molecular profiling is technically challenging due to their physical characteristics and huge heterogeneity.
Previous Work
The previous FET project INDEX has validated at lab scale (TRL4) an integration of a selective sequential isolation and in situ enrichment of small EVs (sEVs) from plasma, with the multiparameter analysis regarding vesicle size, number, and immunophenotype.
Goals of NEXUS
NEXUS aims at proceeding towards industrialization by delivering a manufacturable, full-fledged analytical instrument, characterized by an appealing "sample in - result out" design and featuring a real-time in-liquid measurement of scalable sample volumes.
Breakthrough Technology
NEXUS breakthrough technology will be achieved through the integration of:
- Innovative chemistry for reversible sEVs immunocapture with unique Capture-Release-Re-capture features.
- Microfluidic extraction and pre-concentration of cancer sEVs.
- DNA barcoded customizable chips for single sEV capture and analysis.
Validation and Application
Fully automated Interferometric Reflectance Imaging Sensor providing rapid, sensitive, and multiplex profiling of cancer proteins, displayed on sEVs without the interference of soluble proteins and confounding particles (other sEVs and lipoproteins), will be validated in the relevant industrial and clinical environment and in the context of a Liquid Biopsy assay for Prostate Cancer Stratification, Prognosis, and Monitoring (TRL6).
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.497.750 |
| Totale projectbegroting | € 2.497.750 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 31-5-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CONSIGLIO NAZIONALE DELLE RICERCHEpenvoerder
- IRIS KINETICS INC
- INOREVIA
- DAY ONE SOCIETA A RESPONSABILITA LIMITATA
- UNIVERSITAETSKLINIKUM FREIBURG
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Fully automated cell-free DNA extraction and quantification - liquid biopsies safely from Patient to LabBiopSense aims to develop and validate a fully automated disposable cartridge for cfDNA extraction from blood, enhancing reliability and transport ease for cancer diagnostics and prenatal screening. | EIC Transition | € 2.500.000 | 2022 | Details |
VIVA-ELISA: Advanced Laboratory Test for Rapid Detection of NLRP3 Inflammasome Activation in Critical Septic PatientsVIVA-ELISA aims to develop a rapid, sensitive immunoassay for early detection of NLRP3 inflammasome impairment in sepsis patients to reduce mortality by 25-40% and improve treatment outcomes. | EIC Transition | € 2.493.003 | 2025 | Details |
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samplesThe NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs. | EIC Transition | € 2.499.999 | 2025 | Details |
Revolutionizing Spatial Biology with a cutting-edge Multi-Scale Imaging platformThe NanoSCAN project aims to develop the SAFe-nSCAN platform for high-resolution 3D tissue analysis, enhancing molecular profiling and advancing personalized therapies in immuno-oncology. | EIC Transition | € 2.489.162 | 2023 | Details |
Fully automated cell-free DNA extraction and quantification - liquid biopsies safely from Patient to Lab
BiopSense aims to develop and validate a fully automated disposable cartridge for cfDNA extraction from blood, enhancing reliability and transport ease for cancer diagnostics and prenatal screening.
VIVA-ELISA: Advanced Laboratory Test for Rapid Detection of NLRP3 Inflammasome Activation in Critical Septic Patients
VIVA-ELISA aims to develop a rapid, sensitive immunoassay for early detection of NLRP3 inflammasome impairment in sepsis patients to reduce mortality by 25-40% and improve treatment outcomes.
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples
The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.
Revolutionizing Spatial Biology with a cutting-edge Multi-Scale Imaging platform
The NanoSCAN project aims to develop the SAFe-nSCAN platform for high-resolution 3D tissue analysis, enhancing molecular profiling and advancing personalized therapies in immuno-oncology.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Geintegreerd systeem voor fractionering karakterisatie en kwantificatie van extracellulaire blaasjes en hun inhoudCelnext Biotechnologies onderzoekt de haalbaarheid van een geïntegreerd microfluidisch systeem met optische biosensoren voor gestandaardiseerde isolatie en analyse van extracellulaire blaasjes (EBs). | Mkb-innovati... | € 20.000 | 2021 | Details |
Extracellular Vesicles Fiber Optic Surface Plasmon Resonance selection and analysisFOX has developed an automated, label-free fiber-optic technology for rapid, precise purification and quantification of extracellular vesicles directly from crude samples, enhancing diagnostics and R&D. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Development of nutritional vesicles for precision diagnostics and therapeutics for metabolic diseasesThe NutriEV project investigates food-derived extracellular vesicles as superfoods and biosensors to enhance gut health and metabolic regulation through innovative research and non-invasive biomonitoring. | EIC Pathfinder | € 3.943.243 | 2024 | Details |
Reliable and scalable procedures for the isolation and loading of extracellular vesiclesLABORIOUS aims to develop innovative methods for isolating and loading therapeutic agents into exosomes, enhancing their clinical application in various diseases while minimizing membrane damage. | ERC Proof of... | € 150.000 | 2024 | Details |
Detecting epigenetic biomarkers in the blood for non-invasive precision oncologyDevelop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution. | ERC Starting... | € 1.500.000 | 2022 | Details |
Geintegreerd systeem voor fractionering karakterisatie en kwantificatie van extracellulaire blaasjes en hun inhoud
Celnext Biotechnologies onderzoekt de haalbaarheid van een geïntegreerd microfluidisch systeem met optische biosensoren voor gestandaardiseerde isolatie en analyse van extracellulaire blaasjes (EBs).
Extracellular Vesicles Fiber Optic Surface Plasmon Resonance selection and analysis
FOX has developed an automated, label-free fiber-optic technology for rapid, precise purification and quantification of extracellular vesicles directly from crude samples, enhancing diagnostics and R&D.
Development of nutritional vesicles for precision diagnostics and therapeutics for metabolic diseases
The NutriEV project investigates food-derived extracellular vesicles as superfoods and biosensors to enhance gut health and metabolic regulation through innovative research and non-invasive biomonitoring.
Reliable and scalable procedures for the isolation and loading of extracellular vesicles
LABORIOUS aims to develop innovative methods for isolating and loading therapeutic agents into exosomes, enhancing their clinical application in various diseases while minimizing membrane damage.
Detecting epigenetic biomarkers in the blood for non-invasive precision oncology
Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.